EP1368024A4 - Behandlung von restenose - Google Patents

Behandlung von restenose

Info

Publication number
EP1368024A4
EP1368024A4 EP02707999A EP02707999A EP1368024A4 EP 1368024 A4 EP1368024 A4 EP 1368024A4 EP 02707999 A EP02707999 A EP 02707999A EP 02707999 A EP02707999 A EP 02707999A EP 1368024 A4 EP1368024 A4 EP 1368024A4
Authority
EP
European Patent Office
Prior art keywords
restenosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02707999A
Other languages
English (en)
French (fr)
Other versions
EP1368024A1 (de
Inventor
Alan Husband
Graham Edmund Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marshall Edwards Inc
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR3770A external-priority patent/AUPR377001A0/en
Priority claimed from AUPR5926A external-priority patent/AUPR592601A0/en
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Publication of EP1368024A1 publication Critical patent/EP1368024A1/de
Publication of EP1368024A4 publication Critical patent/EP1368024A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP02707999A 2001-03-16 2002-03-15 Behandlung von restenose Withdrawn EP1368024A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR3770A AUPR377001A0 (en) 2001-03-16 2001-03-16 Treatment of restenosis
AUPR377001 2001-03-16
AUPR5926A AUPR592601A0 (en) 2001-06-26 2001-06-26 Treatment of restenosis
AUPR592601 2001-06-26
PCT/AU2002/000288 WO2002074307A1 (en) 2001-03-16 2002-03-15 Treatment of restenosis

Publications (2)

Publication Number Publication Date
EP1368024A1 EP1368024A1 (de) 2003-12-10
EP1368024A4 true EP1368024A4 (de) 2009-03-18

Family

ID=25646619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02707999A Withdrawn EP1368024A4 (de) 2001-03-16 2002-03-15 Behandlung von restenose

Country Status (3)

Country Link
EP (1) EP1368024A4 (de)
JP (2) JP4256679B2 (de)
WO (1) WO2002074307A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
WO2003086386A1 (en) * 2002-04-09 2003-10-23 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
NZ561574A (en) * 2005-03-24 2010-03-26 Novogen Res Pty Ltd Anti-inflammatory modalities for use against pain, oedema, and erythema (benzotetrahydropyrans, benzopyran derivatives, isoflavonoid derivatives)
GB2443576A (en) * 2005-07-15 2008-05-07 Sahajanand Biotech Private Ltd Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
WO2007016525A2 (en) * 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
ES2454966T3 (es) 2007-02-01 2014-04-14 Resverlogix Corp. Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010045674A1 (en) * 2008-10-22 2010-04-29 Novogen Research Pty Ltd Methods for inducing programmed cell death
TWI472525B (zh) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
CA3146333A1 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
ES2821018T3 (es) 2009-04-22 2021-04-23 Resverlogix Corp Nuevos agentes antiinflamatorios
RS58911B1 (sr) 2011-11-01 2019-08-30 Resverlogix Corp Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
NZ711603A (en) 2014-02-07 2017-05-26 Novogen ltd Functionalised benzopyran compounds and use thereof
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR102005237B1 (ko) * 2017-02-28 2019-07-30 서울대학교산학협력단 에쿠올 유도체를 생산하는 재조합 대장균 및 이를 이용한 에쿠올 유도체 합성 방법
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
EP3797108B1 (de) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulatoren von methyl modifizierenden enzyme, zusammensetzungen und ihre verwendung

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2190411A1 (en) * 1972-06-27 1974-02-01 Blaise Rolland Derivs of 7-hydroxy isoflavones - vascular protectors, antiphlogistics and anti-allergics, prepd from a halocarboxylic acid and a 7-hydroxy isoflavone
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
WO2000030665A1 (en) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
WO2001017986A1 (en) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
WO2000016759A2 (en) * 1998-09-17 2000-03-30 Guido Schnyder Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty
US6413546B1 (en) * 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
AUPQ008399A0 (en) * 1999-04-28 1999-05-27 Novogen Research Pty Ltd Cariovascular applications
AUPQ008299A0 (en) * 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2190411A1 (en) * 1972-06-27 1974-02-01 Blaise Rolland Derivs of 7-hydroxy isoflavones - vascular protectors, antiphlogistics and anti-allergics, prepd from a halocarboxylic acid and a 7-hydroxy isoflavone
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
WO2000030665A1 (en) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
WO2001017986A1 (en) * 1999-09-06 2001-03-15 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG HUEI-CHEN ET AL: "Antiproliferative effect of baicalein, a flavonoid from a Chinese herb, on vascular smooth muscle cell", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 251, no. 1, 1 January 1994 (1994-01-01), pages 91 - 93, XP002349489, ISSN: 0014-2999 *
See also references of WO02074307A1 *
TRAXLER P ET AL: "STRATEGIES TOWARD THE DESIGN OF NOVEL AND SELECTIVE PROTEIN TYROSINE KINASE INHIBITORS", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 82, no. 2/03, 10 June 1999 (1999-06-10), pages 195 - 206, XP000985237, ISSN: 0163-7258 *
TRIEU V N ET AL: "EGF-GENISTEIN INHIBITS NEOINTIMAL HYPERPLASIA AFTER VASCULAR INJURY IN A EXPERIMENTAL RESTENOSIS MODEL", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, vol. 35, no. 4, 1 April 2000 (2000-04-01), pages 595 - 605, XP001011807, ISSN: 0160-2446 *

Also Published As

Publication number Publication date
EP1368024A1 (de) 2003-12-10
JP2009143908A (ja) 2009-07-02
WO2002074307A1 (en) 2002-09-26
JP2004529907A (ja) 2004-09-30
JP4256679B2 (ja) 2009-04-22

Similar Documents

Publication Publication Date Title
GB2393202B (en) Methods of well treatment
EP1368024A4 (de) Behandlung von restenose
EP1385434A4 (de) Behandlung von gewölbeprolaps
GB0121155D0 (en) Treatment of substrates
IL158251A0 (en) Treatment of collagen
GB0109087D0 (en) Treatment of suspensions
HUP0400024A2 (hu) Neoplasztikus betegségek kezelésére szolgáló gyógyszerkombinációk
EP1461027A4 (de) Behandlung von neoplasie
IL150479A0 (en) Treatment of psoriasis
GB0124124D0 (en) Methods of treatment
EP1389105A4 (de) Behandlungsverfahren
GB0103553D0 (en) Substrate treatment
GB0112216D0 (en) Method of treatment
GB0118892D0 (en) Method of treatment
GB0101146D0 (en) Treatment of skin conditions
IL151871A0 (en) Restenosis treatment
IL161630A0 (en) Methods of treating endometreosis
GB0103031D0 (en) Novel treatment
GB0127206D0 (en) Treatment of inflammatory conditions
IL158413A0 (en) Treatment of adhd
AUPR592601A0 (en) Treatment of restenosis
AUPR377001A0 (en) Treatment of restenosis
PL367941A1 (en) The treatment of lipodystrophy
GB0130694D0 (en) Treatment
GB0129451D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090213

17Q First examination report despatched

Effective date: 20091120

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MARSHALL EDWARDS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120308